Table 3 Description of methylation status by methylation-specific PCR (MSP) in relation to main demographic and clinical parameters
From: Recurrence in oral and pharyngeal cancer is associated with quantitative MGMT promoter methylation
| Â | MGMTMethylation (%) | RASSF1methylation (%) | CDKN2Amethylation (%) |
|---|---|---|---|
Gender | Â | Â | Â |
   Male | 14/56 (25.0%) | 4/44 (9.1%) | 5/40 (12.5%) |
   Female | 12/32 (37.5%) | 4/22 (18.2%) | 2/21 (9.5%) |
Smoking status | Â | Â | Â |
   Never smoker | 5/11 (45.5%) | 0/9 (0.0%) | 2/8 (25.0%) |
   Ever smoker | 21/77 (27.3%) | 8/57 (14.0%) | 5/53 (9.4%) |
Alcohol use | Â | Â | Â |
   Never drinker | 4/16 (25.0%) | 0/12 (0.0%) | 4/12 (33.3%)* |
   Ever drinker | 22/72 (30.6%) | 8/54 (14.8%) | 3/49 (6.1%)* |
Family history | Â | Â | Â |
   Negative | 11/41 (26.8%) | 3/35 (8.6%) | 4/30 (13.3%) |
   Positive | 15/47 (31.9%) | 5/31 (16.1%) | 3/31 (9.7%) |
Histology | Â | Â | Â |
   Squamous | 24/85 (28.2%) | 8/65 (12.3%) | 7/60 (11.7%) |
   Other | 2/3 (66.7%) | 0/1 (0.0%) | 0/1 (0.0%) |
Anatomic site | Â | Â | Â |
   Oral cavity & lip | 12/50 (24.0%) | 5/37 (13.5%) | 6/35 (17.1%) |
   Oropharynx | 14/38 (36.8%) | 3/29 (10.3%) | 1/26 (3.8%) |
Stage at diagnosis | Â | Â | Â |
   Local (I, II) | 11/36 (30.6%) | 5/27 (18.5%) | 4/26 (15.4%)* |
   Advanced (III, IV) | 15/52 (28.8%) | 3/39 (7.7%) | 3/35 (8.6%)* |
Treatment | Â | Â | Â |
   Surgery only | 9/44 (20.5%) | 3/26 (11.5%) | 3/24 (12.5%) |
   Surgery and radiotherapy | 16/39 (41.0%) | 5/40 (12.5%) | 4/37 (10.8%) |
   Surgery and chemoradiation | 1/5 (20.0%) | ----- | ----- |
HPV | Â | Â | Â |
   Negative | 18/67 (26.9%) | 7/47 (14.9%) | 7/45 (15.6%) |
   Positive | 8/21 (38.1%) | 1/19 (5.3%) | 0/7 (0.0%) |